Zhejiang VACN Bio-Pharmaceutical

Zhejiang VACN Bio-Pharmaceutical is a Chinese biotechnology company specializing in the development and large-scale production of recombinant protein therapeutics. The company's core focus is the production of Recombinant Human Serum Albumin (rHSA) using a proprietary Pichia pastoris expression system, aiming to provide a safe and scalable alternative to plasma-derived albumin. VACN operates advanced manufacturing facilities in Shaoxing that comply with GMP standards and is currently advancing its lead candidate through Phase 3 clinical trials for indications such as hypoproteinemia and liver cirrhosis. By utilizing yeast-based expression rather than human plasma, the company addresses critical supply shortages and eliminates the risk of blood-borne pathogen transmission. Beyond rHSA, VACN leverages its protein platform to develop other high-value biologics and industrial enzymes for the healthcare sector.